Therapeutic Vaccine Shows Preliminary Safety, Effectiveness for HPV16+ Cervical Precancerous Condition
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 30, 2025 -- For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical intraepithelial neoplasia grade 3 (CIN3), vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness, according to a study published online Jan. 24 in Clinical Cancer Research.
Anneke L. Eerkens, from the University of Groningen in the Netherlands, and colleagues examined the clinical efficacy of Vvax001 in patients with HPV16-positive CIN3. Participants received three immunizations of Vvax001 at a three-week interval and were monitored for regression of CIN3 for up to 19 weeks after the last immunization.
Eighteen patients were enrolled and fully immunized. The researchers found a reduction in CIN3 lesion sizes in 17 of 18 patients (94 percent), which was evident from three weeks onward after the last immunization. Nine of the patients (50 percent) had a histopathological complete response (regression to CIN1 or no dysplasia) and 63 percent of patients had HPV16 clearance. There was no clearance of other HPV types induced by Vvax001. No recurrences have been observed to date, with median and longest disease-free survival of 20 and 30 months, respectively. There were no serious adverse events reported.
"Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 infection in newly diagnosed untreated patients," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
2020 to 2024 Saw Drop in Flu Vaccine Uptake Among U.S. Adults
FRIDAY, July 18, 2025 -- There was an overall decrease in influenza vaccine uptake among U.S. adults from 2020 to 2024, according to a study published online July 16 in PLOS...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.